Collaboration Reinforces Silexion's Commitment to Bringing Transformative RNAi Cancer Therapies to Market as it Advances toward Clinical TrialsGrand Cayman, Cayman Islands, April 23, 2025 (GLOBE ...

GRAND CAYMAN - Silexion Therapeutics Corp. (NASDAQ:SLXN), a micro-cap biotech firm with a market capitalization of $5.92 million focusing on RNA interference therapies for KRAS-driven cancers ...

GRAND CAYMAN - Silexion Therapeutics Corp. (NASDAQ:SLXN), a micro-cap biotech firm with a market capitalization of $5.92 million focusing on RNA interference therapies for KRAS-driven cancers, ...

Silexion Therapeutics Corp. has announced a strategic partnership with Catalent to advance the development of its RNA interference therapy, SIL204, aimed at treating KRAS-driven cancers.

Shares of Silexion Therapeutics Corp (NASDAQ:SLXN – Get Free Report) shot up 46.5% during mid-day trading on Wednesday .The company traded as high as $1.29 and last traded at $1.03. 66,915,194 ...

Silexion’s new expanded dual-route strategy will integrate intratumoral and systemic administration to target both primary tumors and metastases, supported by strong preclinical data from SIL204 ...

Silexion Therapeutics Corp, a biopharmaceutical company, discovers and develops RNA interference (RNAi)-based cancer drugs and delivery systems to treat malignant solid tumors. The company engages ...

Option Chain is currently not available. Nasdaq provides call and put options information of stocks. Financial analysts and individual investors can rely on the chain to gauge the stock's ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...